阅读说明：本技术 一种通过靶向补充bdnf、fto基因配体治疗肥胖的组合物及其制备方法和应用 (Composition for treating obesity through targeted supplement of BDNF and FTO gene ligands and preparation method and application thereof ) 是由 乌林奇 于 2019-09-29 设计创作，主要内容包括：本发明提供了一种通过靶向补充BDNF、FTO基因配体治疗肥胖的组合物及其制备方法和应用,属于营养基因组学技术领域,所述组合物包括以下重量份的原料：车前子壳粉50～200份、燕麦粉50～200份、木瓜粉50～200份、菠萝粉50～200份、西兰花粉50～200份、蓝莓粉5～100份、甘油5～50份、低聚果糖10～30份、抗坏血酸10～40份和矿物质元素补充剂10～40份。本发明通过内源性生成IPA(吲哚丙酸)稳定脑源性神经营养因子BDNF和抑制FTO基因(α-酮戊二酸依赖性双加氧酶)过度表达,靶向补充BDNF、FTO基因配体,从而通过靶向补充BDNF、FTO基因配体治疗肥胖。(The invention provides a composition for treating obesity by targeted supplementation of BDNF and FTO gene ligands and a preparation method and application thereof, belonging to the technical field of nutritional genomics, wherein the composition comprises the following raw materials in parts by weight: 50-200 parts of plantain seed shell powder, 50-200 parts of oat powder, 50-200 parts of papaya powder, 50-200 parts of pineapple powder, 50-200 parts of broccoli powder, 5-100 parts of blueberry powder, 5-50 parts of glycerol, 10-30 parts of fructo-oligosaccharide, 10-40 parts of ascorbic acid and 10-40 parts of a mineral element supplement. According to the invention, the brain-derived neurotrophic factor BDNF is stabilized and the over-expression of FTO gene (alpha-ketoglutarate-dependent dioxygenase) is inhibited through endogenously generating IPA (indolypropionic acid), and BDNF and FTO gene ligands are supplemented in a targeted manner, so that obesity is treated through targeted supplementation of BDNF and FTO gene ligands.)

1. A composition for treating obesity through targeted supplement of BDNF and FTO gene ligands comprises the following raw materials in parts by weight: 50-200 parts of plantain seed shell powder, 50-200 parts of oat powder, 50-200 parts of papaya powder, 50-200 parts of pineapple powder, 50-200 parts of broccoli powder, 5-100 parts of blueberry powder, 5-50 parts of glycerol, 10-30 parts of fructo-oligosaccharide, 10-40 parts of ascorbic acid and 10-40 parts of a mineral element supplement, wherein the mineral element supplement comprises ferrous sulfate and zinc gluconate; the mass ratio of the zinc gluconate to the ferrous sulfate is 0.1-0.2: 0.1-0.2.

2. The composition according to claim 1, characterized in that it comprises the following raw materials in parts by weight: 80-150 parts of plantain seed shell powder, 80-150 parts of oat powder, 80-150 parts of papaya powder, 80-150 parts of pineapple powder, 80-150 parts of broccoli powder, 20-80 parts of blueberry powder, 8-20 parts of glycerol, 15-25 parts of fructo-oligosaccharide, 12-20 parts of ascorbic acid and 12-20 parts of mineral element supplement.

3. The composition according to claim 2, characterized in that it comprises the following raw materials in parts by weight: 100 parts of plantain seed shell powder, 100 parts of oat powder, 100 parts of papaya powder, 100 parts of pineapple powder, 100 parts of broccoli powder, 50 parts of blueberry powder, 10 parts of glycerol, 20 parts of fructo-oligosaccharide, 15 parts of ascorbic acid and 15 parts of mineral element supplement.

4. The composition as claimed in any one of claims 1 to 3, wherein the particle sizes of the Plantain seed husk powder, oat powder, papaya powder, pineapple powder, broccoli powder and blueberry powder are 60 to 100 meshes independently.

5. the composition according to any one of claims 1 to 3, wherein the composition further comprises an adjuvant; the adjuvants include aloe gel powder.

6. The composition as claimed in any one of claims 1 to 3, wherein the dosage form of the composition comprises jelly, powder and oral liquid.

7. A process for the preparation of a composition according to any one of claims 1 to 6, comprising the steps of: mixing the Plantain seed husk powder, oat flour, papaya powder, pineapple powder, broccoli powder, blueberry powder, glycerin, ascorbic acid and mineral supplement, and sterilizing to obtain the composition.

8. Use of the composition of any one of claims 1 to 6 for preparing a food or health product for treating obesity through targeted supplement of BDNF and FTO gene ligands.

Technical Field

the invention relates to the technical field of nutritional genomics, in particular to a composition for treating obesity by targeted supplement of BDNF and FTO gene ligands and a preparation method and application thereof.

Background

Obesity refers to a condition of excess accumulation of body fat, especially triglycerides, due to a degree of significant overweight and an excessively thick fat layer. Obesity shows an increasing trend in the world. About half of obese people are related to genetic factors, and the other half are mainly related to unstable genome and abnormal expression caused by unbalanced nutrients.

At present, weight-losing medicines in the market, such as amphetamine and analogues thereof, have a good effect only on simple obesity, but have more adverse reactions. Multiple researches prove that the fenfluramine, the dexfenfluramine and the compound preparation thereof can cause serious adverse reactions such as heart valve damage, pulmonary hypertension, finger necrosis and the like. Indoles and their derivatives, such as morpholinone and cyclic imidazoles, "burn" excess fat in a thermogenic form, but the drug can raise blood pressure and be detrimental to use by obese patients with cardiovascular disease. L-carnitine and other products can convert fat into energy, and can accelerate weight loss when being matched with exercise, but some people can have symptoms of dizziness, thirst and insomnia. The common phenomenon of the products is dependence, and the rebound can occur quickly when the medicine is stopped.

The BDNF gene is a brain-derived neurotrophic factor and is closely related to susceptibility of bulimia nervosa. The BDNF gene is mutated or can not be normally expressed, and the neuron is excited in an unsteady state, and can continuously send out a nutrient demand signal, so that excessive food intake is caused. Currently, most international researches mainly focus on endogenous or exogenous BDNF administration for preventing and treating neuronal damage, no related targeted drugs or other effective drugs exist, and BDNF gene inactivation even silencing phenomena caused by genotoxic factor combination or hypermethylation, glycosylation modification and the like due to insufficient self BDNF gene ligands are effectively regulated for preventing and treating obesity.

Disclosure of Invention

The invention aims to provide a composition for treating obesity by targeted supplement of BDNF and FTO gene ligands, a preparation method and application thereof.

In order to achieve the above object, the present invention provides the following technical solutions:

The invention provides a composition for treating obesity by targeted supplement of BDNF and FTO gene ligands, which comprises the following raw materials in parts by weight: 50-200 parts of plantain seed shell powder, 50-200 parts of oat powder, 50-200 parts of papaya powder, 50-200 parts of pineapple powder, 50-200 parts of broccoli powder, 5-100 parts of blueberry powder, 5-50 parts of glycerol, 10-30 parts of fructo-oligosaccharide, 10-40 parts of ascorbic acid and 10-40 parts of a mineral element supplement; the mineral element supplement comprises ferrous sulfate and zinc gluconate; the mass ratio of the zinc gluconate to the ferrous sulfate is 0.1-0.2: 0.1-0.2.

Preferably, the composition comprises the following raw materials in parts by weight: 80-150 parts of plantain seed shell powder, 80-150 parts of oat powder, 80-150 parts of papaya powder, 80-150 parts of pineapple powder, 80-150 parts of broccoli powder, 20-80 parts of blueberry powder, 8-20 parts of glycerol, 15-25 parts of fructo-oligosaccharide, 12-20 parts of ascorbic acid and 12-20 parts of mineral element supplement.

Preferably, the composition comprises the following raw materials in parts by weight: 100 parts of plantain seed shell powder, 100 parts of oat powder, 100 parts of papaya powder, 100 parts of pineapple powder, 100 parts of broccoli powder, 50 parts of blueberry powder, 10 parts of glycerol, 20 parts of fructo-oligosaccharide, 15 parts of ascorbic acid and 15 parts of mineral element supplement.

Preferably, the particle sizes of the plantain seed husk powder, the oat powder, the papaya powder, the pineapple powder, the broccoli powder and the blueberry powder are 60-100 meshes independently.

Preferably, the composition further comprises an adjuvant; the adjuvants include aloe gel powder.

Preferably, the dosage form of the composition comprises jelly, powder and oral liquid.

Preferably: mixing the Plantain seed husk powder, oat flour, papaya powder, pineapple powder, broccoli powder, blueberry powder, glycerin, ascorbic acid and mineral supplement, and sterilizing to obtain the composition.

The invention also provides application of the composition in the scheme in preparing food or health care products for treating obesity through targeted supplement of BDNF and FTO gene ligands.

The invention has the beneficial effects that: the invention provides a composition for treating obesity by targeted supplement of BDNF and FTO gene ligands, which comprises the following raw materials in parts by weight: 50-200 parts of plantain seed shell powder, 50-200 parts of oat powder, 50-200 parts of papaya powder, 50-200 parts of pineapple powder, 50-200 parts of broccoli powder, 5-100 parts of blueberry powder, 5-50 parts of glycerol, 10-30 parts of fructo-oligosaccharide, 10-40 parts of ascorbic acid and 10-40 parts of a mineral element supplement; the mineral element supplement comprises ferrous sulfate and zinc gluconate; the mass ratio of the ferrous sulfate to the zinc gluconate is 0.1-0.2: 0.1-0.2.

The invention utilizes the principles of nutritional genomics and molecular nutrition, stabilizes the expression of brain-derived neurotrophic factor BDNF and alpha-ketoglutarate dependent dioxygenase FTO genes by endogenously generating IPA (indolepropionic acid), and supplements BDNF and FTO gene ligands in a targeted manner, thereby treating obesity by supplementing BDNF and FTO gene ligands in a targeted manner.

The BDNF gene has an important ligand IPA (Indole propionic acid) which can stabilize the expression of the BDNF gene and help obese patients to effectively control the bulimia behavior. Meanwhile, IPA can weaken the release of proinflammatory cytokines of the liver by regulating BDNF genes, induce the liver to synthesize free fatty acid, effectively intervene the development of the non-alcoholic fatty liver, and simultaneously, IPA can also influence the function of pancreatic beta cells, promote insulin secretion and prevent type 2 diabetes.

The composition comprises specific dietary fiber components such as plantain seed husk powder, oat flour, papaya powder, pineapple powder, broccoli powder and blueberry powder, wherein the specific plant dietary fibers and fructo-oligosaccharides are metabolized by intestinal flora to generate Indole Propionic Acid (IPA) substances, so that a stable ligand can be provided for a BDNF gene, the expression of the BDNF gene in hippocampus, amygdala, cerebral cortex and cerebellum is stabilized, phospholipase C activity, brain-derived neurotrophic factor receptor signal pathway, cell signals, nerve collateral sprouting, negative regulation and control of myotube differentiation, positive regulation and control of neurotrophic factor TRK receptor signal pathway, brain-derived neurotrophic factor receptor signal pathway, positive regulation and control of receptor binding and regulation of protein positioning to the cell surface are balanced and activated, and the greedy behavior of obese patients is effectively controlled.

The FTO (α -ketoglutarate-dependent dioxygenase) gene is a protein-encoding gene, which is highly expressed in brain tissue, especially in hypothalamus, which controls appetite. The FTO gene is closely related to body mass index, obesity risk and type 2 diabetes. In addition, inactivation or insufficient expression of the FTO gene also affects the expression level of ghrelin, which is a polypeptide produced in the stomach and can enhance appetite, promote ingestion, weaken postprandial satiety of a human and further cause obesity.

The broccoli powder in the composition can stabilize the expression of the FTO gene by cooperating with the glycerol, the ascorbic acid and the mineral element supplement, so that allelic variation caused by gene instability due to insufficient FTO gene element donors can be prevented, and the obesity prevention and treatment can be realized.

Detailed Description

The invention provides a composition for treating obesity by targeted supplement of BDNF and FTO gene ligands, which comprises the following raw materials in parts by weight: 50-200 parts of plantain seed shell powder, 50-200 parts of oat powder, 50-200 parts of papaya powder, 50-200 parts of pineapple powder, 50-200 parts of broccoli powder, 5-100 parts of blueberry powder, 5-50 parts of glycerol, 10-30 parts of fructo-oligosaccharide and 10-40 parts of ascorbic acid and 10-40 parts of mineral element supplement; the mineral element supplement comprises ferrous sulfate and zinc gluconate; the mass ratio of the ferrous sulfate to the zinc gluconate is 0.1-0.2: 0.1-0.2.

In the invention, the composition comprises 50-200 parts of plantain seed husk powder, preferably 80-150 parts, and more preferably 100 parts; the particle size of the Plantain seed husk powder is preferably 60-100 meshes, and more preferably 80 meshes; the plantain seed shell powder is from conventional markets, and in the specific implementation process of the invention, the plantain seed shell powder is from Guangdong era health industry park Co.

In the invention, the composition comprises 50-200 parts of oat flour, preferably 80-150 parts, and more preferably 100 parts; the particle size of the oat powder is preferably 60-100 meshes, and more preferably 80 meshes; the oat flour is from conventional markets, and in the implementation process of the invention, the oat flour is from Guangdong era health industry park company Limited.

In the invention, the composition comprises 50-200 parts of pawpaw powder, preferably 80-150 parts, and more preferably 100 parts; the particle size of the papaya powder is preferably 60-100 meshes, and more preferably 80 meshes; the papaya powder is from conventional markets, and in the specific implementation process of the invention, the papaya powder is from Guangdong era health industry park Co.

in the invention, the composition comprises 50-200 parts of pineapple powder, preferably 80-150 parts, and more preferably 100 parts; the particle size of the pineapple powder is preferably 60-100 meshes, and more preferably 80 meshes; the pineapple powder is from conventional market, and in the specific implementation process of the invention, the pineapple powder is from Guangdong era health industry park Co.

In the invention, the composition comprises 50-200 parts of broccoli powder, preferably 80-150 parts, and more preferably 100 parts; the particle size of the broccoli powder is preferably 60-100 meshes, and more preferably 80 meshes; the broccoli powder preferably contains glycine; the mass percentage of the glycine in the broccoli powder is preferably 0.1-1%, more preferably 0.2-0.8%, and most preferably 0.5%; in the invention, the broccoli powder is rich in glycine component, glycerin and Zn²⁺Synergistic effects provide a stable dioxygenase substrate module for FTO, binding 1 Fe per subunit²⁺Simultaneous quilt of ionsAscorbic acid is activated and can be inhibited by oxalyl glycine, fumarate and succinate; the broccoli powder is from conventional markets, and in the specific implementation process of the invention, the broccoli powder is from Shaanxi Fund Natural products Co.

In the invention, the composition comprises 5-100 parts of blueberry powder, preferably 20-80 parts, and more preferably 50 parts; the particle size of the blueberry powder is preferably 60-100 meshes, and more preferably 80 meshes; the blueberry powder preferably contains anthocyanin; the anthocyanin accounts for 1-50% of the blueberry powder by mass, preferably 5-40% of the blueberry powder by mass, and most preferably 10-20% of the blueberry powder by mass; the blueberry powder is from conventional markets, and in the specific implementation process of the blueberry powder, the biological science and technology company of the great khingan ringer-gesbania zone is provided.

The composition comprises specific dietary fiber components such as plantain seed shell powder, oat flour, papaya powder, pineapple powder, broccoli powder and blueberry powder, wherein the specific plant dietary fibers and fructo-oligosaccharides are metabolized by intestinal flora to generate Indole Propionic Acid (IPA) substances, so that a stable ligand can be provided for a BDNF gene, the expression of the BDNF gene in hippocampus, amygdala, cerebral cortex and cerebellum is stabilized, phospholipase C activity is balanced and activated, a brain-derived neurotrophic factor receptor signal pathway, cell signals, nerve collateral sprouting, negative regulation and control of myotube differentiation, a neurotrophic factor TRK receptor signal pathway, positive regulation and control of a brain-derived neurotrophic factor receptor signal pathway, positive regulation and control of receptor binding and regulation of protein positioning to the cell surface are balanced and activated, and the greedy behavior of obese patients is effectively controlled.

In the invention, the dietary fiber in the composition comprises, but is not limited to, plantain seed husk powder, oat flour, papaya powder, pineapple powder, broccoli powder and blueberry powder, and preferably also comprises strawberry powder and cranberry powder.

In the invention, the composition comprises 5-50 parts of glycerol, preferably 8-20 parts of glycerol, and more preferably 10 parts of glycerol; the glycerol is conventionally commercially available.

In the invention, the composition comprises 10-30 parts of fructo-oligosaccharide powder, preferably 15-25 parts, and more preferably 20 parts; the fructooligosaccharides are derived from conventional commercial sources.

In the invention, the composition comprises 10-40 parts of ascorbic acid, preferably 12-20 parts of ascorbic acid, and more preferably 15 parts of ascorbic acid; the ascorbic acid is commercially available from conventional sources, and in the practice of the present invention, is purchased from Zheng Zhou Rupu bioengineering, Inc.

In the invention, the composition comprises 10-40 parts of mineral element supplement, preferably 12-20 parts, and more preferably 15 parts; the mineral element supplement comprises ferrous sulfate and zinc gluconate; the mass ratio of the zinc gluconate to the ferrous sulfate is 0.1-0.2: 0.1-0.2. Preferably 0.15-0.2: 0.15-0.2, most preferably 0.18-0.2: 0.18-0.2; the zinc gluconate and ferrous sulfate are preferably purchased from Zhengzhou repulping bioengineering, Inc.

In the present invention, the composition preferably further comprises an adjuvant; the auxiliary materials preferably comprise aloe gel powder; the aloe gel powder is preferably aloe vera gel powder which is obtained from conventional commercial sources.

In the present invention, the dosage form of the composition preferably includes jelly, powder and oral liquid.

The invention also provides a preparation method of the composition in the scheme, which comprises the following steps: mixing the plantain seed shell powder, oat powder, papaya powder, pineapple powder, broccoli powder, blueberry powder, glycerin, ascorbic acid and mineral element supplement, and sterilizing according to a plant beverage processing technology to obtain a composition; the present invention is not particularly limited in the manner, time and temperature of the mixing and sterilization, and may be performed by a method conventional in the art.

The invention also provides application of the composition in the scheme in preparing food or health care products for treating obesity through targeted supplement of BDNF and FTO gene ligands.

The technical solutions provided by the present invention are described in detail below with reference to examples, but they should not be construed as limiting the scope of the present invention.